sch 442416 Search Results


sch442416  (Tocris)
94
Tocris sch442416
Effects of purinergic receptor antagonists on IL-2 secretion from activated splenic lymphocytes. Lymphocytes were pre-incubated with 250 μM ATP or ADP and with a P2X receptor inhibitor [PPADS (100 μM), oxATP (300 μM), BDBD (10 μM), A438079 (50 μM), NF449 (10 μM)] (A) , P2Y receptor inhibitor [suramin (100 μM), MRS2578 (10 μM), MRS2211 (100 μM)] (B) , or adenosine receptor inhibitor PSB36 (5 μM), <t>SCH442416</t> (10 μM), PSB603 (10 μM), or MRS3777(10 μM) (C) , and then stimulated with 50 μg/mL ConA for 24 h. Concentrations of IL-2 in the culture medium were measured by ELISA. Significant difference between the vehicle control group and the ConA-treated group in the absence of ligand and inhibitor is indicated by ### P < 0.001. Significant differences between ConA-treated, inhibitor-untreated control (cont) groups and the corresponding inhibitor-treated groups are indicated by ∗∗∗ P < 0.001 and ∗∗ P < 0.01. Each value represents the mean ± SE ( n = 4). Each figure is representative of several independent experiments.
Sch442416, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+442416/SCH+442416/pmc05767601-41-3-13
Average 94 stars, based on 1 article reviews
sch442416 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
2a antagonist sch 442416  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology 2a antagonist sch 442416
Effects of purinergic receptor antagonists on IL-2 secretion from activated splenic lymphocytes. Lymphocytes were pre-incubated with 250 μM ATP or ADP and with a P2X receptor inhibitor [PPADS (100 μM), oxATP (300 μM), BDBD (10 μM), A438079 (50 μM), NF449 (10 μM)] (A) , P2Y receptor inhibitor [suramin (100 μM), MRS2578 (10 μM), MRS2211 (100 μM)] (B) , or adenosine receptor inhibitor PSB36 (5 μM), <t>SCH442416</t> (10 μM), PSB603 (10 μM), or MRS3777(10 μM) (C) , and then stimulated with 50 μg/mL ConA for 24 h. Concentrations of IL-2 in the culture medium were measured by ELISA. Significant difference between the vehicle control group and the ConA-treated group in the absence of ligand and inhibitor is indicated by ### P < 0.001. Significant differences between ConA-treated, inhibitor-untreated control (cont) groups and the corresponding inhibitor-treated groups are indicated by ∗∗∗ P < 0.001 and ∗∗ P < 0.01. Each value represents the mean ± SE ( n = 4). Each figure is representative of several independent experiments.
2a Antagonist Sch 442416, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+442416/SCH+442416/pmc04980770-136-24-38
Average 90 stars, based on 1 article reviews
2a antagonist sch 442416 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
a sch 442416 derivative labeled with a red emitting htrf fluorescent probe  (Cisbio Bioassays)
90
Cisbio Bioassays a sch 442416 derivative labeled with a red emitting htrf fluorescent probe
Effects of purinergic receptor antagonists on IL-2 secretion from activated splenic lymphocytes. Lymphocytes were pre-incubated with 250 μM ATP or ADP and with a P2X receptor inhibitor [PPADS (100 μM), oxATP (300 μM), BDBD (10 μM), A438079 (50 μM), NF449 (10 μM)] (A) , P2Y receptor inhibitor [suramin (100 μM), MRS2578 (10 μM), MRS2211 (100 μM)] (B) , or adenosine receptor inhibitor PSB36 (5 μM), <t>SCH442416</t> (10 μM), PSB603 (10 μM), or MRS3777(10 μM) (C) , and then stimulated with 50 μg/mL ConA for 24 h. Concentrations of IL-2 in the culture medium were measured by ELISA. Significant difference between the vehicle control group and the ConA-treated group in the absence of ligand and inhibitor is indicated by ### P < 0.001. Significant differences between ConA-treated, inhibitor-untreated control (cont) groups and the corresponding inhibitor-treated groups are indicated by ∗∗∗ P < 0.001 and ∗∗ P < 0.01. Each value represents the mean ± SE ( n = 4). Each figure is representative of several independent experiments.
A Sch 442416 Derivative Labeled With A Red Emitting Htrf Fluorescent Probe, supplied by Cisbio Bioassays, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+442416/sch442416+derivative+label+emit+htrf+fluorescent/pm38139329-252-16-29
Average 90 stars, based on 1 article reviews
a sch 442416 derivative labeled with a red emitting htrf fluorescent probe - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
sch-442416  (Molecular Dynamics Inc)
90
Molecular Dynamics Inc sch-442416
Effects of purinergic receptor antagonists on IL-2 secretion from activated splenic lymphocytes. Lymphocytes were pre-incubated with 250 μM ATP or ADP and with a P2X receptor inhibitor [PPADS (100 μM), oxATP (300 μM), BDBD (10 μM), A438079 (50 μM), NF449 (10 μM)] (A) , P2Y receptor inhibitor [suramin (100 μM), MRS2578 (10 μM), MRS2211 (100 μM)] (B) , or adenosine receptor inhibitor PSB36 (5 μM), <t>SCH442416</t> (10 μM), PSB603 (10 μM), or MRS3777(10 μM) (C) , and then stimulated with 50 μg/mL ConA for 24 h. Concentrations of IL-2 in the culture medium were measured by ELISA. Significant difference between the vehicle control group and the ConA-treated group in the absence of ligand and inhibitor is indicated by ### P < 0.001. Significant differences between ConA-treated, inhibitor-untreated control (cont) groups and the corresponding inhibitor-treated groups are indicated by ∗∗∗ P < 0.001 and ∗∗ P < 0.01. Each value represents the mean ± SE ( n = 4). Each figure is representative of several independent experiments.
Sch 442416, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+442416/sch+442416/pm36476719-339-11-0
Average 90 stars, based on 1 article reviews
sch-442416 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
compound sch-442416 (8)  (AstraZeneca ltd)
90
AstraZeneca ltd compound sch-442416 (8)
Effects of purinergic receptor antagonists on IL-2 secretion from activated splenic lymphocytes. Lymphocytes were pre-incubated with 250 μM ATP or ADP and with a P2X receptor inhibitor [PPADS (100 μM), oxATP (300 μM), BDBD (10 μM), A438079 (50 μM), NF449 (10 μM)] (A) , P2Y receptor inhibitor [suramin (100 μM), MRS2578 (10 μM), MRS2211 (100 μM)] (B) , or adenosine receptor inhibitor PSB36 (5 μM), <t>SCH442416</t> (10 μM), PSB603 (10 μM), or MRS3777(10 μM) (C) , and then stimulated with 50 μg/mL ConA for 24 h. Concentrations of IL-2 in the culture medium were measured by ELISA. Significant difference between the vehicle control group and the ConA-treated group in the absence of ligand and inhibitor is indicated by ### P < 0.001. Significant differences between ConA-treated, inhibitor-untreated control (cont) groups and the corresponding inhibitor-treated groups are indicated by ∗∗∗ P < 0.001 and ∗∗ P < 0.01. Each value represents the mean ± SE ( n = 4). Each figure is representative of several independent experiments.
Compound Sch 442416 (8), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+442416/compound+sch+442416++8+/pm17668454-62-0-30
Average 90 stars, based on 1 article reviews
compound sch-442416 (8) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
sch 442416  (MuseChem Chemicals)
N/A
SCH-442416 (Cat No.: I009401) is a highly selective antagonist of the adenosine A2A receptor. It demonstrates strong binding affinity, with Ki values of 0.048 nM for human adenosine A2A receptors and 0.5 nM for rat
   Buy from Supplier
sch-442416  (Aladdin Scientific Corporation)
N/A
SCH-442416 has been used: as a selective adenosine A2A antagonist to study its effects on cyclic adenosine monophosphate (cAMP) production in T/C-28a2 chondrocytes or hFOB 1.19 osteoblasts as a presynaptic A2A receptor antagonists to study
   Buy from Supplier
sch 442416  (BOC Sciences)
N/A
Very selective, high affinity A2A antagonist
   Buy from Supplier
sch-442416  (Selleck Chemicals)
N/A
SCH-442416 is a selective antagonist of adenosine A2A receptor. SCH-442416 binds to human and rat A2A receptors with Ki of 0.048 nM and 0.5 nM, respectively.
   Buy from Supplier
sch 442416  (Cayman Chemical)
N/A
SCH 442416 is a potent brain permeable and selective adenosine A receptor AR antagonist It is selective for AR with a K value of 0 048 nM compared to 1 111 10 000 and 10
   Buy from Supplier
desmethyl sch 442416  (BOC Sciences)
N/A
Desmethyl SCH 442416 is a precursor to [11C]SCH 442416 for PET studies. SCH 442416 is a potent and brain-permeable A2A adenosine receptor antagonist. Desmethyl SCH 442416 is less potent and less selective in binding the
   Buy from Supplier

Image Search Results


Effects of purinergic receptor antagonists on IL-2 secretion from activated splenic lymphocytes. Lymphocytes were pre-incubated with 250 μM ATP or ADP and with a P2X receptor inhibitor [PPADS (100 μM), oxATP (300 μM), BDBD (10 μM), A438079 (50 μM), NF449 (10 μM)] (A) , P2Y receptor inhibitor [suramin (100 μM), MRS2578 (10 μM), MRS2211 (100 μM)] (B) , or adenosine receptor inhibitor PSB36 (5 μM), SCH442416 (10 μM), PSB603 (10 μM), or MRS3777(10 μM) (C) , and then stimulated with 50 μg/mL ConA for 24 h. Concentrations of IL-2 in the culture medium were measured by ELISA. Significant difference between the vehicle control group and the ConA-treated group in the absence of ligand and inhibitor is indicated by ### P < 0.001. Significant differences between ConA-treated, inhibitor-untreated control (cont) groups and the corresponding inhibitor-treated groups are indicated by ∗∗∗ P < 0.001 and ∗∗ P < 0.01. Each value represents the mean ± SE ( n = 4). Each figure is representative of several independent experiments.

Journal: Frontiers in Pharmacology

Article Title: Adenine Nucleotides Attenuate Murine T Cell Activation Induced by Concanavalin A or T Cell Receptor Stimulation

doi: 10.3389/fphar.2017.00986

Figure Lengend Snippet: Effects of purinergic receptor antagonists on IL-2 secretion from activated splenic lymphocytes. Lymphocytes were pre-incubated with 250 μM ATP or ADP and with a P2X receptor inhibitor [PPADS (100 μM), oxATP (300 μM), BDBD (10 μM), A438079 (50 μM), NF449 (10 μM)] (A) , P2Y receptor inhibitor [suramin (100 μM), MRS2578 (10 μM), MRS2211 (100 μM)] (B) , or adenosine receptor inhibitor PSB36 (5 μM), SCH442416 (10 μM), PSB603 (10 μM), or MRS3777(10 μM) (C) , and then stimulated with 50 μg/mL ConA for 24 h. Concentrations of IL-2 in the culture medium were measured by ELISA. Significant difference between the vehicle control group and the ConA-treated group in the absence of ligand and inhibitor is indicated by ### P < 0.001. Significant differences between ConA-treated, inhibitor-untreated control (cont) groups and the corresponding inhibitor-treated groups are indicated by ∗∗∗ P < 0.001 and ∗∗ P < 0.01. Each value represents the mean ± SE ( n = 4). Each figure is representative of several independent experiments.

Article Snippet: PPADS, BDBD, MRS2578, SCH442416, PSB36, MRS3777, A438079, CGS15943, PSB603, and MRS2111 were from Tocris Bioscience (United Kingdom).

Techniques: Incubation, Enzyme-linked Immunosorbent Assay, Control